Recruiting

Parasternal EV-ICD

Sponsor:

AtaCor Medical, Inc.

Code:

NCT07324031

Conditions

Ventricular Arrythmia

Ventricular Fibrillation

Ventricular Tachycardia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atala™ lead and EV-ICD Pulse Generator

Study Details

Brief summary:

The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.

The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.

Conditions

Ventricular Arrythmia

Ventricular Fibrillation

Ventricular Tachycardia

Study ID

NCT07324031

Start date

Jul 2, 2026

Status verified date

Sep, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Aug 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. At least 18 years old
2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion Criteria:

1. Patients who cannot read or write
2. Expected survival < 1 year
3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
4. Participation in any concurrent clinical study without prior approval from the Sponsor
5. Inability or unwillingness to provide informed consent to participate in the study
6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
7. Circumstances that may prevent data collection or completion of specified follow-up visits
8. Allergies to any device materials listed in the Instructions for Use (IFU)
9. Contraindication for temporary suspension of oral/systemic anticoagulation
10. Known history of lung disease with FEV1 < 1.0 Liter

Device Related:
11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
12. Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
13. Any known need for MRI prior to approval of MRI conditional labeling

Anatomy Related:
14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
18. History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
20. Surgically corrected congenital heart disease (not including catheter-based procedures)

Cardiac Related:
21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy
22. Decompensated heart failure
23. Currently on inotropic therapy
24. Known history of pericardial disease, pericarditis or mediastinitis
25. Risk factors associated with defibrillation testing:

  • Severe aortic stenosis
  • Current Intracardiac LA or LV thrombus
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Hemodynamic instability
  • Unstable angina
  • Recent stroke or transient ischemic attack (within the last 3 months)
  • Known inadequate external defibrillation
  • LVEF < 20% (most recent assessment; must be within 180 days of consent)
  • LVEDD >70 mm (most recent assessment; must be within 180 days of consent)

Study Design

Enrollment

280 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Parasternal EV-ICD System

Subjects implanted with the Atala™ lead and EV-ICD pulse generator

Interventions

Atala™ lead and EV-ICD Pulse Generator

Subjects will receive the Atala™ lead and EV-ICD pulse generator being evaluated in the study.

Primary outcome measure

  • Freedom from MADEs [ Time Frame: Through 6 months post-implant ]
  • Successful IVA Test [ Time Frame: At the time of procedure and up to 60 days post-implant ]

Central Contacts and Locations

Central contacts

Locations

St. Bernards Heart and Vascular

Recruiting

Jonesboro, Arkansas, United States, 72401

Principal Investigator:

Devi Nair, MD

Emory University

Recruiting

Atlanta, Georgia, United States, 30308

Principal Investigator:

Mikhael El Chami, MD

Endeavor Health

Recruiting

Glenview, Illinois, United States, 60026

Principal Investigator:

Mark Metzl, MD

Baptist Health

Recruiting

Lexington, Kentucky, United States, 40503

Principal Investigator:

Johan Aasbo, DO

John Hopkins Medical

Recruiting

Baltimore, Maryland, United States, 21287

Principal Investigator:

Edward Powers, MD

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55902

Principal Investigator:

Paul Friedman, MD

Northwell Health

Recruiting

Manhasset, New York, United States, 11030

Principal Investigator:

Laurence Epstein, MD

Advocate/Atrium Health - Sanger Heart and Vascular

Recruiting

Charlotte, North Carolina, United States, 28204

Principal Investigator:

Satish Misra, MD

Advocate/Atrium Health - Wake Forest Baptist

Recruiting

Winston-Salem, North Carolina, United States, 27157

Principal Investigator:

Satish Misra, MD

Texas Cardiac Arrhythmia Research

Recruiting

Austin, Texas, United States, 78705

Principal Investigator:

Amin Al-Ahmad, MD

More Information

Sponsor

AtaCor Medical, Inc.

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Keywords

  • Ventricular Defibrillation
  • Extravascular

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AtaCor Medical, Inc. on 2026-09-03.